Sun nystatin cream recalled for failed stability specifications
Sun Pharmaceutical is recalling specific lots of Nystatin Cream, USP (15 g tubes) because the medication failed stability testing. This means the cream may not maintain its expected strength or safety over time. The affected lots are AD49605 and AD49606, with expiration dates of 05/31/2027.
From the FDA notice · Read the official notice ↗ · All Sun Pharmaceutical recalls
What to do
- Check your prescription nystatin cream for lot number AD49605 or AD49606.
- Contact your pharmacy or doctor if you have one of these lots.
- Do not use the recalled cream; your pharmacy can provide a replacement or alternative.
Is yours affected?
Compare your label or packaging with the recalled product.
- Product
- Nystatin Cream, USP, 15 g per tube, Rx only, Mfd. by: Taro Pharmaceutical Industries Ltd., Haifa Bay, Israel 2624761; Dist. by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532. NDC: 51672-1289-1
- Sold in
- Nationwide
- Made for
- All ages (0 months and older)
Details
- Units affected
- N/A
- Illnesses reported
- None reported
- Manufactured in
- 2 Independence Way, N/A, Princeton, NJ, United States
- Classification
- Not Yet Classified
- Recall number
- 99876
In the FDA's words
- Description
- Nystatin Cream, USP, 15 g per tube, Rx only, Mfd. by: Taro Pharmaceutical Industries Ltd., Haifa Bay, Israel 2624761; Dist. by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532. NDC: 51672-1289-1 Failed Stability Specifications LOT AD49605, LOT AD49606; Exp. 05/31/2027 Distribution: U.S. Nationwide. Affected quantity: N/A
- Hazard
- Failed Stability Specifications
More from Sun Pharmaceutical
See all- Sun Pharma sumatriptan-naproxen tablets recalled, failed dissolution
ModerateFDANov 18, 2026
- Sun Pharmaceutical lisdexamfetamine recalled for failed dissolution
ModerateFDANov 6, 2026
- Taro Tretinoin Cream 0.05% recalled for failed impurity specifications
ModerateFDAOct 14, 2026
- Sun Pharmaceutical Carbamazepine 200mg tablets recalled for manufacturing defect
ModerateFDAAug 26, 2026